Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127964 | 1.00 | ALOX5 (0.46) | ALOX5HDAC4HDAC8MEN1MITF | |
| SCHEMBL4120713 | 0.89 | ALOX5 (0.41) | ALOX5HDAC4HDAC8MEN1RAB9A | |
| SCHEMBL4120717 | 0.89 | ALOX5 (0.41) | ALOX5HDAC4HDAC8MEN1RAB9A | |
| SCHEMBL4792009 | 0.81 | DYRK2 (0.53) | — | |
| SCHEMBL4122944 | 0.80 | ALOX5 (0.48) | ALOX5HDAC4HDAC8 | |
| SCHEMBL4122948 | 0.80 | ALOX5 (0.48) | ALOX5HDAC4HDAC8 | |
| SCHEMBL4133591 | 0.80 | ALOX5 (0.50) | ALOX5HDAC4HDAC8MEN1MITF | |
| SCHEMBL4133593 | 0.80 | ALOX5 (0.50) | ALOX5HDAC4HDAC8MEN1MITF | |
| SCHEMBL4133434 | 0.79 | ALOX5 (0.54) | ALOX5HDAC4HDAC8MEN1MITF | |
| SCHEMBL4133440 | 0.79 | ALOX5 (0.54) | ALOX5HDAC4HDAC8MEN1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | ALOX5 3505/4885HDAC4 2224/4885HDAC8 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.